Co-founders
Dr. Laure C. Bouchez 
Drug hunter with a strong track record of over 7 clinical candidates (from stem cell therapy to small molecules and currently filing an IND for a therapeutic antibodies) and co-author on 10 patents. Published over 40 peered publications and reviews.
Since March 2019. Director, Project team leader Biologics at Glenmark/Ichnos Pharmaceuticals: focusing on areas of developmental and immune processes which hold promise for clinical application.
2011-2019 Research Laboratory Head at NIBR: drug hunter on multiple projects from regenerative medicine to inflammation and oncology.
Dr Guido Koch
Drug hunter and entrepreneur – key contributions to 1 marketed product and 8 clinical candidates. Small molecules, natural products & new modalities. Author or co-author of >45 publications & 10 patents.
Since 2020, Co-founder and CEO Amphilix AG – discovery and development of chimeric small molecules for the treatment of complex diseases.
2018-2020 COO Topadur Pharma AG; Developing biotech startup into a clinical stage venture.
1997-2018 Novartis, Director Global Discovery Chemistry; Immunology, Infectious diseases, drug discovery technology platforms, natural products.
Dr Nicolas Melin
Biologist with 10-year expertise in-vitro assay development and in-vivo tumor model.
Since September 2020 Post Doctoral Fellow at the Visceral and transplantation surgery group of the University of Bern: working on the metabolic changes occurring during liver regeneration.
2014-2020 PhD student at the Visceral and transplantation surgery group of the University of Bern: working on developing critical in-vitro and in-vivo models allowing to understanding radiation-induced liver disease.
2010-2013 Research associate at NIBR: screening, in-vitro pharmacology target validation and assay development.
Javier Asenjo
Technologist, Entrepreneur and investor with experience in tech management roles across industries and a track record of founding businesses in Spain and Germany.
Early investor (with exits) in multiple tech starts ups in the US and India.
2022-Present Technology management in Sportswear /consumer goods industry
2009-2021 Technology management roles in Healthcare/Pharmaceutical companies
2007-2009 Accenture Technology Consultant and Founder.
ADVISORS
Gabriela Gruia
Dr. Gruia is an oncologist by training with more than 25 years of oncology drug development experience across small molecules, biologics, immunotherapy, and cell and gene therapy. Currently Dr. Gruia is the Founder and Independent Consultant at Gabriela Gruia Consulting LLC.
She previously served as Chief Development Officer at Ichnos Sciences, where she oversaw several key functions including Regulatory Sciences, Clinical Operations, Clinical Pharmacology, Biostatistics and Drug Safety.
Previous to Ichnos Sciences Dr. Gruia, was Senior Vice President and Head of Regulatory Affairs for Novartis Oncology, where she was responsible for leading the oncology regulatory affairs organization, and worked in close partnership with research collaborators, preclinical development, the development organization and senior management.
Prior to that, she held senior roles in at Pharmacia/Pfizer and Rhone Poulenc/Aventis, where she designed and conducted Phase I through Phase III clinical trials investigating solid tumor treatments in the metastatic and adjuvant settings.
Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and has a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from Rene Descartes University in Paris France.
Dr Gruia is a member of Tessa Therapeutics Board of Directors; TScan Therapeutics Board of Directors and Molecular Templates Board of Directors.